PUMA BIOTECHNOLOGY (PBYI)

What Could Go Wrong

1. 1Patent cliff exposure with key NERLYNX composition-of-matter patents expiring between 2026-2030, creating generic competition risk within 4-8 years without pipeline replenishment
2. 2Evolving HER2+ breast cancer treatment paradigm with antibody-drug conjugates (Enhertu) demonstrating superior efficacy, potentially marginalizing oral TKI approaches
3. 3Regulatory and reimbursement pressure on specialty pharmaceutical pricing, particularly for products with established competition
4. 4Single-product dependency with no meaningful pipeline diversification creates binary commercial risk
5. 5Dominant competition from Roche (Herceptin, Perjeta, Kadcyla) and Daiichi/AstraZeneca (Enhertu) with superior clinical profiles and market access
6. 6Biosimilar erosion of HER2-targeted therapy market reducing overall pricing and market size for extended adjuvant setting
7. 7Clinical guideline evolution potentially narrowing NERLYNX's target patient population or positioning it as later-line therapy
8. 8Near-zero operating and free cash flow ($0.0B TTM) despite reported profitability raises questions about cash generation sustainability and working capital dynamics

PBYI Chart

My Notes

• value - The stock attracts deep-value investors and special situations funds given 135% one-year return, low valuation multiples (1.6x P/S…
• Rising interest rates create modest headwinds through higher discount rates applied to future cash flows…
• Watch on earnings: NERLYNX total prescription volume (TRx) from IQVIA or Symphony Health data, Quarterly net product revenue and gross-to-net percentage trends, Operating cash flow generation and cash balance adequacy (current ratio 1.74x).